Design and Implementation of the Dual Site Atrial Pacing to Prevent Atrial Fibrillation (DAPPAF) Clinical Trial

Stephanie M. Fitts, M. R S Hill, Rahul Mehra, Paul Andrew Friedman, Stephen Hammill, G. Neal Kay, Atul Prakash, Charles Webb, Sanjeev Saksena

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The Dual Site Atrial Pacing to Prevent Atrial Fibrillation (DAPPAF) study compares dual site, single site and support pacing modalities in the prevention of atrial fibrillation (AF) in patients with a history of paroxysmal AF (PAF) and a bradyarrhythmic indication for pacing. The trial is a randomized crossover comparison of dual site atrial pacing, single site atrial pacing, and a support pacing control period (DDI at 50 ppm or VDI) done in six month intervals. Patient inclusion requires at least 2 documented AF episodes in the three months prior to enrollment. The patients can be on concurrent antiarrhythmic drug regimens but this regimen must remain constant throughout the protocol. Patients with AV nodal ablation are excluded from this study. The primary endpoints of the study compare the time to first recurrence of clinically significant symptomatic AF with ECG verification, and quality of life among the three treatment modes. Secondary endpoints include time to first recurrence of all AF episodes as monitored by the pacemaker, the measurement of echocardiographic parameters, and symptoms logged by the patients. This trial was designed after pilot studies showed dual site pacing to be safe, feasible and preliminary results suggested increased maintenance of sinus rhythm with atrial pacing.

Original languageEnglish (US)
Pages (from-to)139-144
Number of pages6
JournalJournal of Interventional Cardiac Electrophysiology
Volume2
Issue number2
StatePublished - 1998

Fingerprint

Atrial Fibrillation
Clinical Trials
Recurrence
Anti-Arrhythmia Agents
Electrocardiography
Maintenance
Quality of Life

Keywords

  • Atrial fibrillation
  • Clinical trial
  • Dual site pacing
  • Prevention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Design and Implementation of the Dual Site Atrial Pacing to Prevent Atrial Fibrillation (DAPPAF) Clinical Trial. / Fitts, Stephanie M.; Hill, M. R S; Mehra, Rahul; Friedman, Paul Andrew; Hammill, Stephen; Kay, G. Neal; Prakash, Atul; Webb, Charles; Saksena, Sanjeev.

In: Journal of Interventional Cardiac Electrophysiology, Vol. 2, No. 2, 1998, p. 139-144.

Research output: Contribution to journalArticle

Fitts, SM, Hill, MRS, Mehra, R, Friedman, PA, Hammill, S, Kay, GN, Prakash, A, Webb, C & Saksena, S 1998, 'Design and Implementation of the Dual Site Atrial Pacing to Prevent Atrial Fibrillation (DAPPAF) Clinical Trial', Journal of Interventional Cardiac Electrophysiology, vol. 2, no. 2, pp. 139-144.
Fitts, Stephanie M. ; Hill, M. R S ; Mehra, Rahul ; Friedman, Paul Andrew ; Hammill, Stephen ; Kay, G. Neal ; Prakash, Atul ; Webb, Charles ; Saksena, Sanjeev. / Design and Implementation of the Dual Site Atrial Pacing to Prevent Atrial Fibrillation (DAPPAF) Clinical Trial. In: Journal of Interventional Cardiac Electrophysiology. 1998 ; Vol. 2, No. 2. pp. 139-144.
@article{d839f5b37d054eaf8c99f67631a7aa05,
title = "Design and Implementation of the Dual Site Atrial Pacing to Prevent Atrial Fibrillation (DAPPAF) Clinical Trial",
abstract = "The Dual Site Atrial Pacing to Prevent Atrial Fibrillation (DAPPAF) study compares dual site, single site and support pacing modalities in the prevention of atrial fibrillation (AF) in patients with a history of paroxysmal AF (PAF) and a bradyarrhythmic indication for pacing. The trial is a randomized crossover comparison of dual site atrial pacing, single site atrial pacing, and a support pacing control period (DDI at 50 ppm or VDI) done in six month intervals. Patient inclusion requires at least 2 documented AF episodes in the three months prior to enrollment. The patients can be on concurrent antiarrhythmic drug regimens but this regimen must remain constant throughout the protocol. Patients with AV nodal ablation are excluded from this study. The primary endpoints of the study compare the time to first recurrence of clinically significant symptomatic AF with ECG verification, and quality of life among the three treatment modes. Secondary endpoints include time to first recurrence of all AF episodes as monitored by the pacemaker, the measurement of echocardiographic parameters, and symptoms logged by the patients. This trial was designed after pilot studies showed dual site pacing to be safe, feasible and preliminary results suggested increased maintenance of sinus rhythm with atrial pacing.",
keywords = "Atrial fibrillation, Clinical trial, Dual site pacing, Prevention",
author = "Fitts, {Stephanie M.} and Hill, {M. R S} and Rahul Mehra and Friedman, {Paul Andrew} and Stephen Hammill and Kay, {G. Neal} and Atul Prakash and Charles Webb and Sanjeev Saksena",
year = "1998",
language = "English (US)",
volume = "2",
pages = "139--144",
journal = "Journal of Interventional Cardiac Electrophysiology",
issn = "1383-875X",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Design and Implementation of the Dual Site Atrial Pacing to Prevent Atrial Fibrillation (DAPPAF) Clinical Trial

AU - Fitts, Stephanie M.

AU - Hill, M. R S

AU - Mehra, Rahul

AU - Friedman, Paul Andrew

AU - Hammill, Stephen

AU - Kay, G. Neal

AU - Prakash, Atul

AU - Webb, Charles

AU - Saksena, Sanjeev

PY - 1998

Y1 - 1998

N2 - The Dual Site Atrial Pacing to Prevent Atrial Fibrillation (DAPPAF) study compares dual site, single site and support pacing modalities in the prevention of atrial fibrillation (AF) in patients with a history of paroxysmal AF (PAF) and a bradyarrhythmic indication for pacing. The trial is a randomized crossover comparison of dual site atrial pacing, single site atrial pacing, and a support pacing control period (DDI at 50 ppm or VDI) done in six month intervals. Patient inclusion requires at least 2 documented AF episodes in the three months prior to enrollment. The patients can be on concurrent antiarrhythmic drug regimens but this regimen must remain constant throughout the protocol. Patients with AV nodal ablation are excluded from this study. The primary endpoints of the study compare the time to first recurrence of clinically significant symptomatic AF with ECG verification, and quality of life among the three treatment modes. Secondary endpoints include time to first recurrence of all AF episodes as monitored by the pacemaker, the measurement of echocardiographic parameters, and symptoms logged by the patients. This trial was designed after pilot studies showed dual site pacing to be safe, feasible and preliminary results suggested increased maintenance of sinus rhythm with atrial pacing.

AB - The Dual Site Atrial Pacing to Prevent Atrial Fibrillation (DAPPAF) study compares dual site, single site and support pacing modalities in the prevention of atrial fibrillation (AF) in patients with a history of paroxysmal AF (PAF) and a bradyarrhythmic indication for pacing. The trial is a randomized crossover comparison of dual site atrial pacing, single site atrial pacing, and a support pacing control period (DDI at 50 ppm or VDI) done in six month intervals. Patient inclusion requires at least 2 documented AF episodes in the three months prior to enrollment. The patients can be on concurrent antiarrhythmic drug regimens but this regimen must remain constant throughout the protocol. Patients with AV nodal ablation are excluded from this study. The primary endpoints of the study compare the time to first recurrence of clinically significant symptomatic AF with ECG verification, and quality of life among the three treatment modes. Secondary endpoints include time to first recurrence of all AF episodes as monitored by the pacemaker, the measurement of echocardiographic parameters, and symptoms logged by the patients. This trial was designed after pilot studies showed dual site pacing to be safe, feasible and preliminary results suggested increased maintenance of sinus rhythm with atrial pacing.

KW - Atrial fibrillation

KW - Clinical trial

KW - Dual site pacing

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=0032082112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032082112&partnerID=8YFLogxK

M3 - Article

C2 - 9870006

AN - SCOPUS:0032082112

VL - 2

SP - 139

EP - 144

JO - Journal of Interventional Cardiac Electrophysiology

JF - Journal of Interventional Cardiac Electrophysiology

SN - 1383-875X

IS - 2

ER -